We strive for openness and honesty in all aspects of our business and are committed to full disclosure of clinical trial data and the initiatives and organisations that we fund in line with the requirements of our industry.


Transfers of Value


Shionogi operates in Europe via Shionogi B.V. a private limited liability company formed under Dutch law, Shionogi GmbH in Germany, Shionogi S.r.l in Italy and Shionogi SLU in Spain. Transfers of value initiated by any company in the Shionogi European Group to HCPs, HCOs and ORDMs resident in UK are disclosed via the abpi disclosure database. The methodology used in these transfer of value calculations is available here.


Transfers of value to HCP's, HCO's and ORDM's within Europe (calendar year 2018) where Shionogi does not have a local presence are listed here.

Shionogi GroupClinical Trial Data Transparency Policy

The Shionogi group Clinical Trial Data Transparency Policy can be found here.

Clinical Trial Data

Shionogi understand the benefit of ensuring clinical trial data is shared with healthcare providers, patients, and the general public.

In accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) principles on clinical trial data sharing, we are committed to reviewing requests from researchers for access to clinical trial protocols, patient-level clinical trial data and study-level clinical trial data. In addition, we will ensure that synopses of clinical study reports for medicines that have been granted marketing authorisations, after the authorisation process has concluded, are made publically available.


Given that we have a UK establishment located in the UK, these measures must support the current requirements in the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. The ABPI stipulate that current and future trials must be registered within 21 days of enrolling the first patient, and results must be published within one year of marketing authorisation or one year from completion for marketed products.

Detailed information on our current development areas can be found at ClinicalTrials.Gov and Clinicaltrialsregister.eu.


NP-EU-NP-0101 dop May 2020